Y-mAbs Therapeutics, Inc. (YMAB)
| Market Cap | 130.57M |
| Revenue (ttm) | 43.42M |
| Net Income (ttm) | -133.62M |
| Shares Out | 43.67M |
| EPS (ttm) | -3.06 |
| PE Ratio | n/a |
| Forward PE | 119.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 245,014 |
| Open | 3.20 |
| Previous Close | 3.12 |
| Day's Range | 2.94 - 3.20 |
| 52-Week Range | 2.94 - 20.48 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 10.58 (+253.85%) |
| Earnings Date | Mar 23, 2023 |
About YMAB
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neurob... [Read more]
Financial Performance
In 2021, YMAB's revenue was $34.90 million, an increase of 68.18% compared to the previous year's $20.75 million. Losses were -$55.28 million, -53.68% less than in 2020.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is $10.58, which is an increase of 253.85% from the latest price.
News
Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, ...
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023
NEW YORK , March 20, 2023 /PRNewswire/ -- Attention Y-mAbs Therapeutics, Inc. ("Y-mAbs") (NASDAQ: YMAB) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced...
Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options
NEW YORK , March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") ...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 20, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investor...
YMAB SHAREHOLDER ALERT: Jakubowitz Law Reminds Y-mAbs Shareholders of a Lead Plaintiff Deadline of March 20, 2023
NEW YORK , March 17, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB). To ...
YMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , March 16, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) of a class action securities lawsuit. CLASS D...
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mA...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 20 Deadline in Securities Class Action - YMAB
NEW YORK , March 15, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) between October 6, 20...
YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit
BENSALEM, Pa. , March 15, 2023 /PRNewswire/ -- Law Offices of Howard G.
Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
Did you lose money on investments in Y-mAbs Therapeutics? If so, please visit Y-mAbs Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernli...
YMAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 20, 2023 in the Class Action Filed on Behalf of Y-mAbs Therapeutics, Inc. Shareholders
NEW YORK , March 14, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) alleging that ...
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 13, 2023 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-m...
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mA...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB
NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB). Such investors are advis...
Bronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively Participate
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Co...
Y-MABS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options
NEW YORK , March 11, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") ...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
NEW YORK , March 8, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) between October 6, 20...
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
NEW YORK , March 1, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) between October 6, 202...
ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
NEW YORK , Feb. 23, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) between October 6, 20...
Y-MABS THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB
NEW ORLEANS , Feb. 21, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 20, ...
Y-mAbs Shareholder Action Reminder
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Co...
NATIONALLY RANKED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
New York, New York--(Newsfile Corp. - February 17, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) betw...
YMAB LOSS ALERT: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
NEW YORK , Feb. 16, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) between October 6, 202...
Y-mAbs Class Action: Levi & Korsinsky Reminds Y-mAbs Therapeutics, Inc. Investors of The Pending Class Action Lawsuit With a Lead Plaintiff Deadline of March 20, 2023 - YMAB
New York, New York--(Newsfile Corp. - February 16, 2023) - Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) of a class action securities...
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Y-mAbs Therapeutics, Inc. (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.